Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26494161 | 1.00 | HRH3 (0.40) | HRH3KCNH2CYP2D6BIRC2KDM4E | |
| SCHEMBL26494364 | 1.00 | HRH3 (0.40) | HRH3KCNH2CYP2D6BIRC2KDM4E | |
| SCHEMBL25075211 | 0.92 | GAA (0.42) | HRH3KCNH2CYP2D6KDM4ELMNA | |
| SCHEMBL25075112 | 0.90 | KDM4E (0.42) | HRH3KCNH2CYP2D6BIRC2KDM4E | |
| SCHEMBL25075143 | 0.86 | HRH3 (0.39) | HRH3KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL26494162 | 0.86 | HRH3 (0.39) | HRH3KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL26496254 | 0.86 | HRH3 (0.39) | HRH3KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL26494371 | 0.84 | NPC1 (0.40) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26494372 | 0.84 | NPC1 (0.40) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26494171 | 0.84 | NPC1 (0.40) | HRH3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | HRH3 3222/4885KCNH2 4681/4885CYP2D6 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.